J. Lijnsvelt

402 total citations
9 papers, 47 citations indexed

About

J. Lijnsvelt is a scholar working on Oncology, Molecular Biology and Computational Theory and Mathematics. According to data from OpenAlex, J. Lijnsvelt has authored 9 papers receiving a total of 47 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Molecular Biology and 2 papers in Computational Theory and Mathematics. Recurrent topics in J. Lijnsvelt's work include Cancer Immunotherapy and Biomarkers (6 papers), Melanoma and MAPK Pathways (5 papers) and Cutaneous Melanoma Detection and Management (3 papers). J. Lijnsvelt is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Melanoma and MAPK Pathways (5 papers) and Cutaneous Melanoma Detection and Management (3 papers). J. Lijnsvelt collaborates with scholars based in Netherlands, Italy and Finland. J. Lijnsvelt's co-authors include Alexander Christopher Jonathan Van Akkooi, Matteo S. Carlino, Christian U. Blank, W. Martin C. Klop, Alexander M. Menzies, Kerwin F. Shannon, Richard A. Scolyer, Shahneen Sandhu, Maria Gonzalez and Georgina V. Long and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

J. Lijnsvelt

6 papers receiving 47 citations

Peers

Countries citing papers authored by J. Lijnsvelt

Since Specialization

Citations

This map shows the geographic impact of J. Lijnsvelt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Lijnsvelt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Lijnsvelt more than expected).

Fields of papers citing papers by J. Lijnsvelt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Lijnsvelt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Lijnsvelt. The network helps show where J. Lijnsvelt may publish in the future.

Co-authorship network of co-authors of J. Lijnsvelt

This figure shows the co-authorship network connecting the top 25 collaborators of J. Lijnsvelt. A scholar is included among the top collaborators of J. Lijnsvelt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Lijnsvelt. J. Lijnsvelt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial. 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), Alexander M. Menzies, (unknown), Robyn P.M. Saw, Winan J. van Houdt, Mark B. Faries, Caroline Robert, Paolo A. Ascierto, Célèste Lebbé, Matteo S. Carlino, Ellen Kapiteijn, Karijn P.M. Suijkerbuijk, Piotr Rutkowski, Shahneen Sandhu, (unknown), Georgina V. Long, Christian U. Blank, Lonneke V. van de Poll‐Franse, J. Lijnsvelt	0
2	Electronic patient-reported outcomes, fever management, and symptom prediction among patients with BRAF V600 mutant stage III–IV melanoma: The Kaiku Health platform 2024 ·SHILAP Revista de lepidopterología ·Peter Mohr, Paolo A. Ascierto, Alfredo Addeo, Maria Grazia Vitale, Paola Queirolo, Christian U. Blank, Jussi Ekström, (unknown), Vesa Kataja, (unknown), (unknown), (unknown), Ailís Fagan, (unknown), Rubén Marques, J. Lijnsvelt	1
3	The MARIANE-trial: Multicenter phase 1b/2 trial testing safety and efficacy of neoadjuvant intradermal ipilimumab and nivolumab in high-risk stage II melanoma. 2024 ·Journal of Clinical Oncology ·Lotte Hoeijmakers, Anke Kuijpers, Bart A. van de Wiel, Marta López‐Yurda, Elsemieke I. Plasmeijer, Charlotte L. Zuur, (unknown), (unknown), (unknown), J. Lijnsvelt, Alfonsus Johannes Maria van den Eertwegh, Mathilde Jalving, Ellen Kapiteijn, Karijn P.M. Suijkerbuijk, (unknown), Bart Jacobs, Tanja D. de Gruijl, Christian U. Blank	2
4	CN3 Patient adherence to digital patient-reported outcome monitoring (PROM) in cancer immunotherapies 2023 ·Annals of Oncology ·J. Lijnsvelt, (unknown), Sanna Iivanainen, Maria Grazia Vitale, (unknown), (unknown), Peter G. Mohr, Alfredo Addeo, Paolo A. Ascierto, Jussi Koivunen, Ellinor Haukland, Christian U. Blank	0
5	854P Clinical features of acquired resistance (AR) in stage IV melanoma patients (pts) treated with immune checkpoint inhibition (ICI) 2022 ·Annals of Oncology ·Judith M. Versluis, (unknown), (unknown), Sofie Wilgenhof, A. Meerveld-Eggink, Henk Mallo, Wilma Uyterlinde, J. Lijnsvelt, J.B.A.G. Haanen, (unknown)	1
6	840P Electronic patient-reported outcomes (ePROs) of adults with BRAF V600–mutant stage III-IV melanoma treated with dabrafenib + trametinib (D + T) collected using the Kaiku Health digital patient (pt) monitoring platform 2022 ·Annals of Oncology ·J. Lijnsvelt, Alfredo Addeo, Maria Giuseppa Vitale, Peter G. Mohr, Paola Queirolo, (unknown), (unknown), (unknown), (unknown), A.D. Fagan, Mike Lau, (unknown), (unknown), (unknown), Paolo A. Ascierto	2
7	The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma. 2022 ·Journal of Clinical Oncology ·(unknown), J. Lijnsvelt, (unknown), Richard A. Scolyer, Alexander M. Menzies, Alexander Christopher Jonathan Van Akkooi, Winan J. van Houdt, Kerwin F. Shannon, Thomas E. Pennington, Karijn P.M. Suijkerbuijk, Ellen Kapiteijn, (unknown), Matteo S. Carlino, Shahneen Sandhu, Maria Gonzalez, Charlotte L. Zuur, W. Martin C. Klop, Georgina V. Long, Christian U. Blank	34
8	Phase II study comparing pembrolizumab (PEM) with intermittent/short‐term dual MAPK pathway inhibition plus PEM in patients harboring the BRAFV600 mutation (IMPemBra) 2018 ·Annals of Oncology ·(unknown), Karolina Sikorska, Lindsay G. Grijpink-Ongering, (unknown), Bart A. van de Wiel, Ayşegül Sarı, Henk Mallo, S. Adriaansz, Wilma Uyterlinde, J. Lijnsvelt, Loes M. Pronk, J.B.A.G. Haanen, Jan Willem B. de Groot, Sofie Wilgenhof, (unknown), Johannes V. van Thienen, Christian U. Blank	7
9	Switch to checkpoint inhibition (CPI) after targeted therapy (TT) at time of progression or during ongoing response: A retrospective analysis of patients with advanced BRAF mutated melanoma 2018 ·Annals of Oncology ·Irene L. M. Reijers, Elisa A. Rozeman, Henk Mallo, Wilma Uyterlinde, S. Adriaansz, J. Lijnsvelt, Sofie Wilgenhof, Johannes V. van Thienen, J.B.A.G. Haanen, (unknown)	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact